NCT02363803View on ClinicalTrials.gov

Lidocaine for Diabetic Peripheral Neuropathy

NACompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

October 17, 2018

Study Completion Date

October 17, 2018

Conditions
DiabetesPeripheral NeuropathyPain
Interventions
DRUG

lidocaine

lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.

DRUG

Placebo

Normal saline, approved for hypovolemia, and homeostasis.

Trial Locations (1)

63110

Washington University School of Medicine/Barnes Jewish Hospital, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT02363803 - Lidocaine for Diabetic Peripheral Neuropathy | Biotech Hunter | Biotech Hunter